Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.
Salmeterol was granted FDA approval on 4 February 1994.
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT00876694
- Locations
- 🇯🇵
Novartis Investigator site, Sapporo, Japan
🇯🇵Novartis Investigator Site, Yokohama, Japan
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1123
- Registration Number
- NCT00821093
- Locations
- 🇺🇸
Novartis Investigative Center, Clearwater, Florida, United States
🇺🇸Novartis Investigative site, Spartanburg, South Carolina, United States
🇩🇪Novartis Investgative Site, Witten, Germany
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
- Conditions
- Lung DiseasesPulmonary Disease, Chronic ObstructiveLung Diseases, Obstructive
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 405
- Registration Number
- NCT00808288
- Locations
- 🇹🇷
Pfizer Investigational Site, Izmir, Turkey
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
- Conditions
- Allergic Asthma
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- University of Rostock
- Target Recruit Count
- 35
- Registration Number
- NCT00736801
- Locations
- 🇩🇪
University of Rostock, Rostock, Germany
The Effects of Montelukast on Smokers With Asthma
- Conditions
- Asthmatic SmokersNon-asthmatic Smokers
- Interventions
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Inje University
- Target Recruit Count
- 105
- Registration Number
- NCT00712335
- Locations
- 🇰🇷
Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 255
- Registration Number
- NCT00706446
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- COPD
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 717
- Registration Number
- NCT00685841
Tiotropium and Salmeterol PK Study in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT00673478
- Locations
- 🇧🇪
1184.24.32001 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇧🇪1184.24.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇳🇱1184.24.31001 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands
Tiotropium/Salmeterol Inhalation Powder in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tiotropium/SalmeterolDrug: Placebo
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 207
- Registration Number
- NCT00668772
- Locations
- 🇱🇻
1184.15.37153 Boehringer Ingelheim Investigational Site, Tukums, Latvia
🇺🇸1184.15.01071 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
🇩🇰1184.15.45054 Boehringer Ingelheim Investigational Site, Aalborg, Denmark
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tiotropium/Salmeterol QDDrug: Placebo
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 220
- Registration Number
- NCT00662740
- Locations
- 🇺🇸
1184.14.01006 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
🇺🇸1184.14.01015 Boehringer Ingelheim Investigational Site, South Bend, Indiana, United States
🇳🇱1184.14.31001 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.